Berenberg Bank set a €89.95 ($104.59) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research report sent to investors on Thursday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
FME has been the subject of a number of other research reports. Independent Research set a €74.00 ($86.05) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research report on Monday, June 17th. JPMorgan Chase & Co. set a €56.70 ($65.93) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Monday, June 24th. Nord/LB set a €92.00 ($106.98) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Friday, May 3rd. HSBC set a €101.00 ($117.44) price objective on shares of Grenke and gave the company a buy rating in a research report on Thursday, April 25th. Finally, Barclays restated a hold rating and issued a $14.00 price objective on shares of MACOM Technology Solutions in a research report on Thursday, June 20th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of €82.57 ($96.01).
Shares of FME opened at €69.70 ($81.05) on Thursday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of €55.44 ($64.47) and a fifty-two week high of €91.74 ($106.67). The firm has a market capitalization of $21.28 billion and a P/E ratio of 10.85. The business’s 50-day simple moving average is €68.10. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 100.05.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading: Liquidity
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.